Nelson and colleagues (2009) stated that the National Breast and Ovarian Cancer Center's position statement on population screening and early detection of ovarian cancer in asymptomatic women was developed and agreed following a Forum in February 2009 attended by key Australian stakeholders. The final position statement and supporting background information have been endorsed by key Australian colleges and agencies. Position statement on population screening and early detection of ovarian cancer in asymptomatic women noted that (i) currently there is no evidence that any test, including pelvic examination, CA-125 or other biomarkers, ultrasound (including TV-US), or combination of tests, results in reduced mortality from ovarian cancer, and (ii) there is no evidence to support the use of any test, including pelvic examination, CA-125 or other biomarkers, ultrasound (including TV-US), or combination of tests, for routine population-based screening for ovarian cancer.
Our goal with this publication is to help primary care physicians, psychiatrists, pharmacists, obstetricians, midwives, public health nurses and nurse practitioners provide the best advice, information and care to women who are taking psychotropic medications or other substances during pregnancy and postpartum. Medications and other substances discussed in this handbook have been chosen because of their psychotropic qualities: they all affect brain chemistry and functioning. Drugs and substances that are not psychotropic, that are not used during pregnancy, or about whose effects there is not enough documented evidence (., herbal remedies) are not included.